Details of the Drug

General Information of Drug (ID: DMZBU15)

Drug Name
Tripelennamine
Synonyms
Benzoxale; Cizaron; Dehistin; Piribenzil; Pyribenzamin; Pyribenzamine; Pyridbenzamine; Resistamine; Tonaril; Tripelannamine; Tripelenamina; Tripelenamine; Tripelennamin; Tripelennamina; Tripelennaminum; Tripellenamine; Triplennamine; Vetibenzamina; Pyrinamine base; Tripelennamina [Italian]; Tripelennamine [BAN]; Tripelennamine [INN]; Ts and Blues; Pyribenzamine (TN); Pyristine (piristina); Tripelenamina [INN-Spanish]; Tripelennamine (INN); Tripelennaminum [INN-Latin]; Tripelennamine Citrate (1:1); Beta-Dimethylaminoethyl-2-pyridylaminotoluene; Beta-Dimethylaminoethyl-2-pyridylbenzylamine; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(alpha.-pyridyl)-dimethylaethylendiamin; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; N,N-Dimethyl-N'-benzyl-N'-(alpha.-pyridyl)ethylenediamine; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-(9CI); 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Hypersensitivity 4A80-4A85 Approved [2]
Urticaria EB00-EB05 Approved [1]
Vasomotor/allergic rhinitis CA08 Approved [1]
Pruritus EC90 Investigative [1]
Therapeutic Class
Antiallergic Agents
Affected Organisms
Humans and other mammals
ATC Code
D04AA04: Tripelennamine
D04AA: Antihistamines for topical use
D04A: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04: ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D: DERMATOLOGICALS
R06AC04: Tripelennamine
R06AC: Substituted ethylene diamines
R06A: ANTIHISTAMINES FOR SYSTEMIC USE
R06: ANTIHISTAMINES FOR SYSTEMIC USE
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 255.36
Logarithm of the Partition Coefficient (xlogp) 3.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The drug is well absorbed in the digestive tract []
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C16H21N3
IUPAC Name
N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine
Canonical SMILES
CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2
InChI
InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3
InChIKey
UFLGIAIHIAPJJC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5587
ChEBI ID
CHEMBL1241
CAS Number
91-81-6
UNII
3C5ORO99TY
DrugBank ID
DB00792
TTD ID
D0B4JQ
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tripelennamine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Tripelennamine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [4]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Tripelennamine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [4]
Coadministration of a Drug Treating the Disease Different from Tripelennamine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Tripelennamine and Memantine. Alzheimer disease [8A20] [5]
Rivastigmine DMG629M Moderate Antagonize the effect of Tripelennamine when combined with Rivastigmine. Alzheimer disease [8A20] [6]
Donepezil DMIYG7Z Moderate Antagonize the effect of Tripelennamine when combined with Donepezil. Alzheimer disease [8A20] [6]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Tripelennamine and Desipramine. Attention deficit hyperactivity disorder [6A05] [5]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Tripelennamine and Cariprazine. Bipolar disorder [6A60] [5]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Tripelennamine and Loperamide. Bowel habit change [ME05] [7]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Tripelennamine when combined with Acetylcholine. Cataract [9B10] [8]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [9]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Tripelennamine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [9]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Tripelennamine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [9]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Tripelennamine and Ethanol. Cystitis [GC00] [10]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Tripelennamine and Cyclobenzaprine. Depression [6A70-6A7Z] [5]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Tripelennamine and Isocarboxazid. Depression [6A70-6A7Z] [11]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Tripelennamine and OPC-34712. Depression [6A70-6A7Z] [5]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Tripelennamine and Clomipramine. Depression [6A70-6A7Z] [5]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Tripelennamine and Doxepin. Depression [6A70-6A7Z] [5]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Tripelennamine and Maprotiline. Depression [6A70-6A7Z] [5]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Tripelennamine and Esketamine. Depression [6A70-6A7Z] [12]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Tripelennamine and Mepenzolate. Digestive system disease [DE2Z] [4]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Tripelennamine and Oxybutynine. Discovery agent [N.A.] [5]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Tripelennamine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [13]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Tripelennamine and Diphenhydramine. Episodic vestibular syndrome [AB31] [5]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Tripelennamine and Solifenacin. Functional bladder disorder [GC50] [5]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Tolterodine. Functional bladder disorder [GC50] [5]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Tripelennamine when combined with Pilocarpine. Glaucoma [9C61] [8]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Tripelennamine and Procarbazine. Hodgkin lymphoma [2B30] [11]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Tripelennamine and Belladonna. Infectious gastroenteritis/colitis [1A40] [5]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Amantadine. Influenza [1E30-1E32] [14]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Tripelennamine and ITI-007. Insomnia [7A00-7A0Z] [5]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Tripelennamine and Dicyclomine. Irritable bowel syndrome [DD91] [5]
Physostigmine DM2N0TO Moderate Antagonize the effect of Tripelennamine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [6]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Tripelennamine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [15]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Tripelennamine and Flibanserin. Mood disorder [6A60-6E23] [16]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Tripelennamine and Thalidomide. Multiple myeloma [2A83] [10]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Dimenhydrinate. Nausea/vomiting [MD90] [5]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Tripelennamine and Promethazine. Nausea/vomiting [MD90] [5]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Tripelennamine and Apraclonidine. Optic nerve disorder [9C40] [17]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Tripelennamine and Flavoxate. Pain [MG30-MG3Z] [5]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Tripelennamine and Biperiden. Parkinsonism [8A00] [4]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Tripelennamine and Orphenadrine. Parkinsonism [8A00] [5]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Tripelennamine and Methylscopolamine. Peptic ulcer [DA61] [5]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Tripelennamine and Quetiapine. Schizophrenia [6A20] [5]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Tripelennamine and Mesoridazine. Schizophrenia [6A20] [4]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Tripelennamine and Aripiprazole. Schizophrenia [6A20] [5]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Tripelennamine and Iloperidone. Schizophrenia [6A20] [5]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Tripelennamine and Paliperidone. Schizophrenia [6A20] [5]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Tripelennamine and Perphenazine. Schizophrenia [6A20] [5]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Tripelennamine and Molindone. Schizophrenia [6A20] [5]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Thiothixene. Schizophrenia [6A20] [5]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Tripelennamine and Trifluoperazine. Schizophrenia [6A20] [5]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Asenapine. Schizophrenia [6A20] [5]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Tripelennamine and Pimozide. Schizophrenia [6A20] [5]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [5]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Tripelennamine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [5]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Tripelennamine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [4]
⏷ Show the Full List of 55 DDI Information of This Drug

References

1 Tripelennamine FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309.
4 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
5 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
6 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
7 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
8 Multum Information Services, Inc. Expert Review Panel.
9 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
10 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
11 Canadian Pharmacists Association.
12 Cerner Multum, Inc. "Australian Product Information.".
13 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
14 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
15 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
16 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
17 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.